Sorafenib in elderly patients with advanced hepatocellular carcinoma: A case series

Oncology (Switzerland)

Volumn 84, Issue 5, 2013, Pages 265-272

  Montella, Liliana ^a   Addeo, Raffaele ^a   Cennamo, Gregorio ^a   Vincenzi, Bruno ^c   Palmieri, Rita ^a   Sperlongano, Pasquale ^b   Sperlongano, Rossella ^b   Iodice, Patrizia ^a   Russo, Paola ^a   Del Prete, Salvatore ^a  

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Elderly patients; Hepatocellular carcinoma; Sorafenib; Targeted therapy

Indexed keywords

SORAFENIB; BILIRUBIN;

AGED; ARTICLE; ASCITES; ASTHENIA; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE ESCALATION; ELDERLY CARE; FEMALE; HUMAN; HYPOALBUMINEMIA; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL TIME; THROMBOSIS; TREATMENT OUTCOME; ADVANCED CANCER; ANOREXIA; BILIRUBIN BLOOD LEVEL; CANCER STAGING; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOLLOW UP; GERIATRIC PATIENT; HAND FOOT SYNDROME; LIVER CIRRHOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874002381     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000345558     Document Type: Article

References (30)

1. Castello G, Scala S, Palmieri G, Curley SA, Izzo F: HCV-related hepatocellular carcinoma: from chronic inflammation to cancer. Clin Immunol 2010; 134:237-250.
2. Sarbah SA, Gramlich T, Younoszai A, Osmack P, Goormastic M, Grosso L, Cooper JN, Di Bisceglie A, Seneca R, Younossi ZM: Risk factors for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci 2004; 49:850-853.
3. N'Kontchou G, Paries J, Htar MT, Ganne-Carrie N, Costentin L, Grando-Lemaire V, Trinchet JC, Beaugrand M: Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenter-ol Hepatol 2006; 4:1062-1068.
4. Horner MJ, Ries LAG, Krapcho M: SEER Cancer Statistics Review, 1975-2006. Bethes-da, National Cancer Institute. http://seer.can-cer.gov/csr/1975-2006/ (accessed December 1, 2009).
5. Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491.
6. Kozyreva ON, Chi D, Clark JW, Wang H, Theall KP, Ryan DP, Zhu AX: A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma. Oncologist 2011; 16:310-318.
7. Bosetti C, Bianchi C, Negri E, Colombo M, La Vecchia C: Estimates of the incidence and prevalence of hepatocellular carcinoma in Italy in 2002 and projections for the years 2007 and 2012. Tumori 2009; 95:23-27.
8. Addeo R, Caraglia M, Del Prete S: Highlights of regional meeting of Italian Southern Oncological Group (GOIM). Focus on hepatocel-lular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives. 7 November 2008, Naples, Italy. Expert Opin Investig Drugs 2009; 18:373-378.
9. Pignata S, Gallo C, Daniele B, Elba S, Giorgio A, Capuano G, Adinolfi LE, De Sio I, Izzo F, Farinati F, Del Naja C, Stanzione M, Casti-glione F, Marone G, Cuomo O, Felder M, Gaeta GB, De Maio E, Di Maio M, Signoriello G, Perrone F: Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly: a study of the Cancer of the Liver Italian Program (CLIP). Crit Rev Oncol Hematol 2006; 59:243-249.
10. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061-2067.
11. Montella L, Addeo R, Caraglia M, Del Prete S: Latest developments in targeted therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther 2010; 10:1635-1646.
12. Balducci L: Geriatric oncology: challenges for the new century. Eur J Cancer 2000; 36:1741-1754.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
14. Kats S: Assessing self-maintenance; activities of daily living, mobility and instrumental activities of daily living. J Am Geriatr Soc 1983; 31:721-727.
15. Zanocchi M, Ponzetto M, Francisetti F, Mae-ro B, Giona E, Amati D, Nicola E, Corsinovi L, Cerrato F, Luppino A, Margolicci A, Mo-laschi M, Fabris F: The dependence medical index (DMI): validation and comparison with the activity daily living and the instrumental activity daily living. Minerva Med 2004; 95: 143-151.
16. Yount S, Cella D, Webster K, Heffernan N, Chang C, Odom L, van Gool R: Rapid assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index (FHSI-8). J Pain Symptom Manage 2002; 24: 32-44.
17. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat As-soc 1958; 53:457-481.
18. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
19. Caraglia M, Tassone P, Marra M, Budillon A, Venuta S, Tagliaferri P: Targeting Raf-kinase: molecular rationales and translational issues. Ann Oncol 2006; 17(suppl 7):vii124-127.
20. ®) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008; 61:535-548.
21. Cheng AL, Kang YK, Chen Z, Tsao C-J, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang T-S, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocel-lular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34.
22. Del Prete S, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Feb-braro A, Tarantino L, Capasso E, Palmieri G, Guarrasi R, Bianco M, Mamone R, Savastano C, Pisano A, Vincenzi B, Sabia A, D'Agostino A, Faiola V, Addeo R: Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Che-mother Pharmacol 2010; 66:837-844.
23. Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hains-worth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA: Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology 2010; 78:340-347.
24. Morimoto M, Numata K, Kondo M, Hidaka H, Takada J, Shibuya A, Kobayashi S, Ohkawa S, Okuse C, Morita S, Taguri M, Tanaka K: Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res 2011; 41:296-302.
25. Wong H, Tang FY, Yao T-Y, Chiu J, Leung R, Chan P, Cheung TT, Chan AC, Pang RW, Poon, Fan S-T, Yau T: The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepa-tocellular carcinoma (HCC). Oncologist 2011; 16:1721-1728.
26. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B: Safety, pharmacokinet-ics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007; 12:426-437.
27. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Cammà C, Colombo M; SOFIA (SOraFenib Italian Assessment) Study Group: Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54:2055-2063.
28. Kim JE, Ryoo BY, Ryu MH, Chang HM, Suh DJ, Lee HC, Lim YS, Kim KM, Kang YK: Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma. Oncology 2012; 82:119-125.
29. Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul JL: Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RE-CIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118:147-156.
30. Tsukui Y, Mochizuki H, Hoshino Y, Kawaka-mi S, Kuno T, Fukasawa Y, Iwamoto F, Hirose S, Yoshida T, Hosoda K, Suzuki Y, Hosoda K, Kojima Y, Hirose Y, Shindou K, Matsuda M, Yagawa S, Tawara A, Kobayashi M, Konishi T, Yamazaki T, Takahashi S, Fujii H, Enomoto N, Omata M: Factors contributing to the overall survival in patients with hepatocellu-lar carcinoma treated by sorafenib. Hepato-gastroenterology 2012; 12:59.